<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192374</url>
  </required_header>
  <id_info>
    <org_study_id>D153-P513</org_study_id>
    <nct_id>NCT00192374</nct_id>
  </id_info>
  <brief_title>Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Children</brief_title>
  <official_title>A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase III, Multicenter Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A &amp; B,Live, Cold-Adapted (CAIV-T) in Healthy Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      - Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels
      of a Liquid Formulation of(CAIV-T) in Healthy Children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      - A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase III, Multicenter Trial
      to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a
      Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A &amp; B, Live Cold-Adapted
      (CAIV-T) in Healthy Children
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date>November 2002</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint was the first episode in a study child of a culture-confirmed influenza illness, caused by community-acquired subtypes antigenically similar to those contained in the vaccine.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>A secondary efficacy endpoint was the first episode of culture-confirmed influenza illness caused by any community-acquired antigenic subtype.</measure>
  </secondary_outcome>
  <enrollment>1920</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAIV-T, Liquid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  •who are aged at least 6 months and less than 36 months of age at the time of first
             vaccination

               -  who are in good health as determined by medical history, physical examination and
                  clinical judgement

               -  whose parent(s)/legal guardian(s) have provided written informed consent after
                  the nature of the study has been explained

               -  who, along with their parent(s)/legal guardian(s), will be available for duration
                  of the trial (8 months ±1 month)

               -  whose parent(s)/legal guardian(s), can be reached by study staff for the
                  post-vaccination contacts [telephone, clinic or home visit].

        Exclusion Criteria:

          -  whose parent(s)/legal guardian(s) are perceived to be unavailable or difficult to
             contact for evaluation or study visits during the study period with any serious
             chronic disease (e.g., with signs of cardiac or renal failure or severe malnutrition),
             including progressive neurological disease

               -  with Down's syndrome or other known cytogenetic disorders

               -  with a known or suspected disease of the immune system or those receiving
                  immunosuppressive therapy, including systemic corticosteroids (see Section 4.2.1)

               -  who received any blood products, including immunoglobulin, in the period from six
                  months prior to vaccination through to the conclusion of the study

               -  for whom there is intent to administer any other investigational vaccine or agent
                  from one month prior to enrollment through to the conclusion of the study

               -  have an immunosuppressed or an immunocompromised individual living in the same
                  household

               -  who, at any time prior to entry into this study, received a dose of any influenza
                  vaccine (commercial or investigational)

               -  with a documented history of hypersensitivity to egg or egg protein or any other
                  component of the assigned study vaccine

               -  who received aspirin (acetylsalicylic acid) or aspirin-containing products in the
                  two weeks prior to vaccination or for which use is anticipated during the study

               -  with any medical conditions that in the opinion of the investigator might
                  interfere with interpretation of the study results. If any of these criteria are
                  met following enrolment, the subject will be excluded from subsequent vaccine
                  dosing.

        Note: Pregnancy in a household member or any person who has regular contact with the
        subject is not a contraindication to the enrollment or ongoing participation of the subject
        in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tawee Chotpitayasunondh, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Sirikit National Institute of Child Health (Children's Hospital)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosario Z. Capeding, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Microbiology, Research Institute for Tropical Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Microbiology, Research Institute for Tropical Medicine</name>
      <address>
        <city>Muntinlupa City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Sirikit National Institute of Child Health (Children's Hospital)</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>October 2, 2006</last_update_submitted>
  <last_update_submitted_qc>October 2, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2006</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

